Casein Kinase II Inhibitor IV structure
|
Common Name | Casein Kinase II Inhibitor IV | ||
---|---|---|---|---|
CAS Number | 863598-09-8 | Molecular Weight | 429.47100 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C24H23N5O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Casein Kinase II Inhibitor IVCasein Kinase II Inhibitor IV is a small-molecule inducer of epidermal keratinocyte differentiation. |
Name | 3-[3-[2-(3,4,5-trimethoxyanilino)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]propanenitrile |
---|---|
Synonym | More Synonyms |
Description | Casein Kinase II Inhibitor IV is a small-molecule inducer of epidermal keratinocyte differentiation. |
---|---|
Related Catalog | |
Target |
Target: Casein Kinase[1] |
In Vitro | Treatment of human epidermal keratinocytes (NHEKs) with Casein Kinase II Inhibitor IV leads to an increase in the early differentiation markers keratins 1 and 10 at 48 h. Increased levels of IVL and TGM are observed in cells treated with Casein Kinase II Inhibitor IV at 72 h and persisted at 96 h. In addition, treated with Casein Kinase II Inhibitor IV expressesloricrin, a terminal differentiation marker, at later time points. Similar results are observed by messenger RNA (mRNA) expression analysis of NHEKs treated with Casein Kinase II Inhibitor IV. At early time points (12 and 24 h), treatment with Casein Kinase II Inhibitor IV leads to the upregulation of keratinocyte early differentiation marker genes, including keratin 1 (5.4-fold) and keratin 10 (5.4-fold). Terminal differentiation marker genes, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), are upregulated at late time points (36 and 48 h). These results are again consistent with the ability of Casein Kinase II Inhibitor IV to induce differentiation of epidermal progenitor cells into terminally differentiated keratinocytes[1]. |
Kinase Assay | For reporter gene assays with transiently transfected cells, the cells are typically transfected in 150 mm-diam dishes when 30-40% confluent. A reporter plasmid, pGL3/3.7 kbp-IVLLuc plasmid, is transfected into the NHEKs. After 24 h, the transfected cells are plated into 96-well assay plates and treated with compound (Casein Kinase II Inhibitor IV) to a final concentration of 5 μM. After incubation for 2 d, reporter gene activity is measured using the Bright-Glo luciferase assay system[1]. |
References |
Molecular Formula | C24H23N5O3 |
---|---|
Molecular Weight | 429.47100 |
Exact Mass | 429.18000 |
PSA | 94.22000 |
LogP | 4.71908 |
Storage condition | 2-8℃ |
Keratinocyte Differentiation Inducer |
3-{3-[2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-phenyl}-propionitrile |
HMS3229D03 |
Casein Kinase II Inhibitor IV |